FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol

UnknownOBSERVATIONAL
Enrollment

2,500

Participants

Timeline

Start Date

October 2, 2023

Primary Completion Date

February 29, 2024

Study Completion Date

March 30, 2024

Conditions
Influenza AInfluenza Type BSARS CoV 2 InfectionRSV Infection
Interventions
DIAGNOSTIC_TEST

Diagnostic Test for identification of influenzas A, influenzas B, RSV and SARS-CoV-2 infections

"The FINDER FLU A/B, RSV, SARS-CoV-2 Test real-time RT-PCR test for the qualitative detection of viral RNA from RSV, FLU A, FLU B and SARS-CoV-2 in nasopharyngeal (NP) specimens from individuals suspected of respiratory tract infection by their healthcare provider.~Nucleic acids from respiratory viruses identified by this test are typically detectable in nasopharyngeal swabs (NP) during the acute phase of infection. The detection and identification of specific viral nucleic acids from individuals signs is an indication of the presence of the identified microorganism and assist in the diagnosis of respiratory infection when considered alongside other clinical and epidemiological information."

Trial Locations (1)

27610

Wake Med, Raleigh

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Baebies, Inc.

INDUSTRY

NCT05928507 - FINDER® Instrument and FINDER® FLU A/B, RSV, SARS-CoV-2 Test Clinical Evaluation Protocol | Biotech Hunter | Biotech Hunter